Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2012, Article ID 587672, 7 pages
http://dx.doi.org/10.1155/2012/587672
Research Article

Immunohistochemical Expression and Prognostic Value of CD97 and Its Ligand CD55 in Primary Gallbladder Carcinoma

Department of Hepatobiliary Pancreatic Surgery, Huai'an First People's Hospital Nanjing Medical University, Jiangsu, Huai'an 223300, China

Received 25 November 2011; Accepted 25 January 2012

Academic Editor: Soldano Ferrone

Copyright © 2012 Jinsheng Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. S. Kim, K. T. Jang, D. W. Choi et al., “Clinicopathologic analysis of adenosquamous/squamous cell carcinoma of the gallbladder,” Journal of Surgical Oncology, vol. 103, no. 3, pp. 239–242, 2011. View at Publisher · View at Google Scholar · View at PubMed
  2. F. Miura, T. Asano, H. Amano et al., “New prognostic factor influencing long-term survival of patients with advanced gallbladder carcinoma,” Surgery, vol. 148, no. 2, pp. 271–277, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. Z. H. Hu, Z. W. Li, L. Shen, M. Zhang, and S. S. Zheng, “Surgical therapy and prognosis of sarcomatoid carcinoma of the gallbladder,” Hepatobiliary and Pancreatic Diseases International, vol. 9, no. 2, pp. 175–179, 2010. View at Google Scholar · View at Scopus
  4. M. J. Kwakkenbos, E. N. Kop, M. Stacey et al., “The EGF-TM7 family: a postgenomic view,” Immunogenetics, vol. 55, no. 10, pp. 655–666, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. S. Lea, “Interactions of CD55 with non-complement ligands,” Biochemical Society Transactions, vol. 30, no. 6, pp. 1014–1019, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Visser, A. F. De Vos, J. Hamann et al., “Expression of the EGF-TM7 receptor CD97 and its ligand CD55 (DAF) in multiple sclerosis,” Journal of Neuroimmunology, vol. 132, no. 1-2, pp. 156–163, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. R. M. Hoek, D. De Launay, E. N. Kop et al., “Deletion of either CD55 or CD97 ameliorates arthritis in mouse models,” Arthritis and Rheumatism, vol. 62, no. 4, pp. 1036–1042, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. S. L. Han, C. Xu, X. L. Wu, J. L. Li, Z. Liu, and Q. Q. Zeng, “The impact of expressions of CD97 and its ligand CD55 at the invasion front on prognosis of rectal adenocarcinoma,” International Journal of Colorectal Disease, vol. 25, no. 6, pp. 695–702, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. R. D. Loberg, K. J. Wojno, L. L. Day, and K. J. Pienta, “Analysis of membrane-bound complement regulatory proteins in prostate cancer,” Urology, vol. 66, no. 6, pp. 1321–1326, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. L. G. Durrant, M. A. Chapman, D. J. Buckley, I. Spendlove, R. A. Robins, and N. C. Armitage, “Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients,” Cancer Immunology, Immunotherapy, vol. 52, no. 10, pp. 638–642, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. Y. Liu, L. Chen, S. Peng et al., “The expression of CD97EGF and its ligand CD55 on marginal epithelium is related to higher stage and depth of tumor invasion of gastric carcinomas,” Oncology reports., vol. 14, no. 6, pp. 1413–1420, 2005. View at Google Scholar · View at Scopus
  12. Y. Liu, L. Chen, S. Y. Peng, Z. X. Chen, and C. Hoang-Vu, “Role of CD97stalk and CD55 as molecular markers for prognosis and therapy of gastric carcinoma patients,” Journal of Zhejiang University: Science, vol. 6, no. 9, pp. 913–918, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. W. Remmele and H. E. Stegner, “Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue,” Pathologe, vol. 8, no. 3, pp. 138–140, 1987. View at Google Scholar · View at Scopus
  14. W. S. Kim, D. W. Choi, D. D. You, C. Y. Ho, J. S. Heo, and S. H. Choi, “Risk factors influencing recurrence, patterns of recurrence, and the efficacy of adjuvant therapy after radical resection for gallbladder carcinoma,” Journal of Gastrointestinal Surgery, vol. 14, no. 4, pp. 679–687, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. T. Mustafa, A. Eckert, T. Klonisch et al., “Expression of the epidermal growth factor seven-transmembrane member CD97 correlates with grading and staging in human oral squamous cell carcinomas,” Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 1, pp. 108–119, 2005. View at Google Scholar · View at Scopus
  16. M. J. Kwakkenbos, W. Pouwels, M. Matmati et al., “Expression of the largest CD97 and EMR2 isoforms on leukocytes facilitates a specific interaction with chondroitin sulfate on B cells,” Journal of Leukocyte Biology, vol. 77, no. 1, pp. 112–119, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. M. Wobus, B. Vogel, E. Schmücking, J. Hamann, and G. Aust, “N-glycosylation of CD97 within the EGF domains is crucial for epitope accessibility in normal and malignant cells as well as CD55 ligand binding,” International Journal of Cancer, vol. 112, no. 5, pp. 815–822, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. D. Liu, B. Trojanowicz, Y. Radestock et al., “Role of CD97 isoforms in gastric carcinoma,” International Journal of Oncology, vol. 36, no. 6, pp. 1401–1408, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Wobus, O. Huber, J. Hamann, and G. Aust, “CD97 overexpression in tumor cells at the invasion front in colorectal cancer (CC) is independently regulated of the canonical Wnt pathway,” Molecular Carcinogenesis, vol. 45, no. 11, pp. 881–886, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. T. Mustafa, T. Klonisch, S. Hombach-Klonisch et al., “Expression of CD97 and CD55 in human medullary thyroid carcinomas,” International journal of oncology, vol. 24, no. 2, pp. 285–294, 2004. View at Google Scholar · View at Scopus
  21. W. P. Zhao, B. Zhu, Y. Z. Duan, and Z. T. Chen, “Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells,” Oncology Reports, vol. 21, no. 6, pp. 1405–1411, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Geis, S. Zell, R. Rutz et al., “Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro,” Current Cancer Drug Targets, vol. 10, no. 8, pp. 922–931, 2010. View at Google Scholar
  23. J. Dzietczenia, T. Wróbel, G. Mazur, R. Porȩba, B. Jaźwiec, and K. Kuliczkowski, “Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20(+) non-Hodgkin's lymphoma,” Medical Oncology, vol. 27, no. 3, pp. 743–746, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus